Related Experiment Video
Updated: Sep 3, 2025
Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
Published on: May 2, 2019
Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy
Kaili Deng1,2, Dongxue Yang1,3, Yuping Zhou1,3
1Department of Gastroenterology and Hepatology, The Affiliated Hospital of Medical School, Ningbo University, Ningbo 315020, China.
Abstract:
Immune evasion is a common reason causing the failure of anticancer immune therapy. Small interfering RNA (siRNA), which can activate the innate and adaptive immune system responses by silencing immune-relevant genes, have been demonstrated to be a powerful tool for preventing or reversing immune evasion. However, siRNAs show poor stability in biological fluids and cannot efficiently cross cell membranes. Nanotechnology has shown great potential for intracellular siRNA delivery in recent years. Nano-immunotherapy can efficiently penetrate the tumor microenvironment (TME) and deliver multiple immunomodulatory agents simultaneously, which appears to be a promising method for combination therapy. Therefore, it provides a new perspective for siRNA delivery in immunomodulation and cancer immunotherapy. The current advances and challenges in nanotechnology-based siRNA delivery strategies for overcoming immune evasion will be discussed in this review. In addition, we also offer insights into therapeutic options, which may expand its applications in clinical cancer treatment.
Insights
Nanotechnology enhances small interfering RNA (siRNA) delivery for cancer immunotherapy by overcoming immune evasion. This nano-immunotherapy approach improves stability and cell penetration, offering new treatment options.
Area of Science:
- Oncology
- Immunology
- Nanotechnology
- Biotechnology
Background:
- Anticancer immune therapy often fails due to tumor immune evasion.
- Small interfering RNA (siRNA) can modulate immune responses but faces delivery challenges.
- Nanotechnology offers solutions for intracellular siRNA delivery and overcoming biological barriers.
Purpose of the Study:
- To review advances in nanotechnology-based siRNA delivery for cancer immunotherapy.
- To discuss strategies for overcoming immune evasion using nano-immunotherapy.
- To explore therapeutic insights for clinical applications.
Main Methods:
- Review of current literature on nanotechnology and siRNA delivery.
- Analysis of nano-immunotherapy strategies for tumor microenvironment penetration.
- Discussion of challenges and future directions in siRNA-based cancer treatment.
Main Results:
- Nanotechnology significantly improves siRNA stability and cellular uptake.
- Nano-immunotherapy enables efficient delivery of multiple immunomodulatory agents.
- Targeted delivery via nanotechnology overcomes tumor immune evasion.
Conclusions:
- Nanotechnology-based siRNA delivery is a promising strategy for overcoming immune evasion in cancer immunotherapy.
- Nano-immunotherapy presents a viable approach for combination therapy and enhanced treatment efficacy.
- Further research can expand the clinical application of these strategies in cancer treatment.
Related Concept Videos
01:27Tumor Immunotherapy
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:15Experimental RNAi
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:30Small interfering RNAs (siRNA)